Oncotelic Therapeutics, Inc.
OTLC- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000908259
In the last 90 days, Oncotelic Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $10.3K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding OTLC, Q2 2026
No superinvestor reported holding OTLC at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Oncotelic Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2026 (view filing)3:00 PM ET | Jul 1 | 1 day | Trieu VuongCHAIRMAN AND CEO | PPurchase | +240.0K | $0.0431 | +$10.3K | +0.3%94.1M after | |
| Jun 24, 2026 (view filing)8:37 PM ET | Jun 22-24 | 2 days | Trieu VuongCHAIRMAN AND CEO | PPurchase | +255.0K | $0.045 | +$11.5K | +0.3%93.7M after | 3 lots |
| Jun 22, 2026 (view filing)4:30 PM ET | Jun 22 | Same day | Shah Amit B.CFO | PPurchase | +20.0K | $0.05 | +$1.00K | +5.6%378.8K after | |
| Jun 17, 2026 (view filing)7:34 PM ET | Jun 15-17 | 2 days | Trieu VuongCHAIRMAN AND CEO | PPurchase | +335.8K | $0.0447 | +$15.0K | +0.4%93.4M after | 2 lots |
| Jul 10, 2025 (view filing)5:15 PM ET | Jul 8-10 | 2 days | Trieu VuongCHAIRMAN AND CEO | PPurchase | +198.7K | $0.005 | +$993.69 | +0.2%93.4M after | 3 lots |
| Jan 31, 2025 (view filing)5:08 PM ET | Jan 29-31 | 2 days | Trieu VuongCHAIRMAN AND CEO | PPurchase | +346.8K | $0.028 | +$9.71K | +0.4%93.2M after | 3 lots |
| Nov 26, 2024 (view filing)11:33 AM ET | Nov 22 | 4 days | Trieu VuongCHAIRMAN AND CEO | PPurchase | +298.5K | $0.0289 | +$8.63K | +0.3%92.8M after | |
| Aug 27, 2024 (view filing)8:00 AM ET | Aug 23 | 4 days | Trieu VuongCHAIRMAN AND CEO | PPurchase | +500.0K | $0.02 | +$10.0K | +0.5%92.5M after | |
| Jun 30, 2023 (view filing)9:25 AM ET | Jun 28-29 | 2 days | Trieu VuongCHAIRMAN AND CEO | PPurchase | +500.0K | $0.0218 | +$10.9K | +0.5%91.6M after | 2 lots |
| Jun 20, 2023 (view filing)12:00 PM ET | Jun 16 | 4 days | Trieu VuongCHAIRMAN AND CEO | PPurchase | +100.0K | $0.026 | +$2.60K | +0.1%91.5M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Oncotelic Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding OTLC in 13F filings for Q2 2026.